Our Research
We have identified four critical research areas that are key to achieving our goal of ending Parkinson’s. These priorities will lead the way to faster drug development and more targeted treatments.
We’re working to understand what Parkinson’s is, when it begins and how it differs by person to enable more targeted treatments.
We provide early funding for the most promising yet highest-risk therapies, moving them from the lab into human trials.
We’re developing new tools to detect and measure Parkinson’s and revolutionizing how trials are run.
We harness the power of patients, families, researchers, policymakers and advocates to accelerate a cure for Parkinson’s.
Biotech, pharma and academic-industry partnerships are encouraged to apply for funding to advance therapies with strong scientific promise.
Chief Scientist Mark Frasier shares why research into the overlapping biology of neurodegenerative diseases matters for people living with Parkinson’s.
Research progress relies on participation from people with and without Parkinson’s disease. Learn how you can join a clinical trial.
How will we cure Parkinson’s? Since the start, our research strategy has been to find and fund the most promising research — and go all in. Today, that has become a robust and sophisticated ecosystem of scientific programs and initiatives. Real progress can be felt across the field. But we won’t be satisfied until our work is done, and a future without Parkinson’s is a reality.
We bring researchers, funders and industry partners together to deepen understanding of Parkinson’s biology and translate promising discoveries into meaningful treatments.
ASAP is a global coordinated initiative to better understand the underlying causes of Parkinson’s disease.
PPMI fuels discovery of new biomarkers and scientific advances that further our understanding of Parkinson’s.
Guided by a global community of researchers, this initiative is identifying and validating promising targets for future Parkinson’s treatments.
By funding early-stage research, we de-risk promising therapies and help them move from discovery to clinical testing.
This comprehensive initiative connects global experts to fast-track LRRK2-based therapies and identify and validate new biomarkers.
The Path to Prevention platform trial will investigate early intervention for people at risk for Parkinson’s.
Everyone can play a vital role in our work toward better treatments and a cure for Parkinson’s.
Researchers from academia and industry are invited to apply for funding in support of ways to define, measure and treat Parkinson’s.
Research needs a vital partner: You. Join a study and help unlock new discoveries and better treatments.
Your voice is powerful. Join our policy network and tell your elected officials to take action now.
MJFF helped validate a biomarker test that detects Parkinson’s biology before symptoms begin. Watch how this breakthrough is paving the way for precision medicine, told by friends of the Foundation.
